Literature DB >> 10773023

Extracellular signal-regulated kinases are involved in the antiapoptotic effect of endothelin-1.

J R Wu-Wong1, W J Chiou, J Wang.   

Abstract

An imbalance between proliferation and apoptosis is an important causal factor for disorders involving abnormal cell accumulation. The role and mechanism of how G protein-coupled receptors are linked to apoptosis are poorly understood. Endothelin-1 (ET-1), a 21-amino acid peptide that binds to G protein-coupled receptors with mitogenic and vasoconstricting activities, suppressed apoptosis of human prostatic smooth muscle cells induced by paclitaxel treatment or serum withdrawal. Serum withdrawal or paclitaxel (1-10 microM) treatment for 48 h resulted in DNA fragmentation, a characteristic of apoptosis. The addition of ET-1 attenuated DNA fragmentation. The attenuating effect of ET-1 on DNA fragmentation was not affected by wortmannin, bisindolylmaleimide I, tyrphostin AG490, or AG1478. However, PD98059, an inhibitor for the extracellular signal-regulated kinase (ERK) kinase, induced apoptosis, potentiated the effect of serum withdrawal on inducing apoptosis, and blocked the antiapoptotic effect of ET-1. The ERK1/2 activity in these cells decreased rapidly after paclitaxel treatment or serum withdrawal, but was maintained at a 2-fold higher level in the presence of ET-1 for at least 4 h. These results suggest that the ERK1/2 pathway is activated by ET-1, and blocking this pathway abolishes the antiapoptotic effect of ET-1.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10773023

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Src-family tyrosine kinases, phosphoinositide 3-kinase and Gab1 regulate extracellular signal-regulated kinase 1 activation induced by the type A endothelin-1 G-protein-coupled receptor.

Authors:  S Bisotto; E D Fixman
Journal:  Biochem J       Date:  2001-11-15       Impact factor: 3.857

2.  Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity.

Authors:  Maria Vaiou; Evanthia Pangou; Panagiotis Liakos; Nikos Sakellaridis; George Vassilopoulos; Konstantinos Dimas; Christos Papandreou
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-16       Impact factor: 4.553

3.  Characterization of a streptococcal endopeptidase with homology to human endothelin-converting enzyme.

Authors:  J Oetjen; P Fives-Taylor; E Froeliger
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

4.  Endothelin Confers Protection against High Glucose-Induced Neurotoxicity via Alleviation of Oxidative Stress.

Authors:  Mohamed A Fouda; Abdel A Abdel-Rahman
Journal:  J Pharmacol Exp Ther       Date:  2017-02-08       Impact factor: 4.030

5.  Endothelin-1 inhibits apoptosis in prostate cancer.

Authors:  Joel B Nelson; Michael S Udan; Georgi Guruli; Beth R Pflug
Journal:  Neoplasia       Date:  2005-07       Impact factor: 5.715

6.  Extracellular signal-regulated kinase plays an essential role in endothelin-1-induced homotypic adhesion of human neutrophil granulocytes.

Authors:  Levente József; Tarek Khreiss; Alain Fournier; John S D Chan; János G Filep
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

7.  Inhibitory effect of endothelin A receptor blockade on tumor growth and liver metastasis of a human gastric cancer cell line.

Authors:  Rika Fukui; Hidefumi Nishimori; Fumitake Hata; Takahiro Yasoshima; Keisuke Ohno; Yoshiyuki Yanai; Kenjiro Kamiguchi; Ryuichi Denno; Noriyuki Sato; Koichi Hirata
Journal:  Gastric Cancer       Date:  2007-06-25       Impact factor: 7.370

8.  Atrasentan (ABT-627) enhances perfusion and reduces hypoxia in a human tumor xenograft model.

Authors:  Kwang Mo Yang; James Russell; Mihaela E Lupu; Hyungjoon Cho; Xiao-Feng Li; Jason A Koutcher; C Clifton Ling
Journal:  Cancer Biol Ther       Date:  2009-10-22       Impact factor: 4.742

Review 9.  Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures.

Authors:  Xuan Huang; Cindy H Chau; William D Figg
Journal:  J Hematol Oncol       Date:  2012-07-02       Impact factor: 17.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.